Ventas, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Ventas, Inc. (NYSE: VTR) on May 12, 2026, covering events occurring between May 12, 2026, and May 15, 2026. The filing addresses executive departures, the results of the 2026 Annual Meeting of Stockholders, and an amendment to the Company's At-The-Market (ATM) equity sales agreement.
Key Financial Metrics and Capital Structure
The filing does not report operational financial metrics such as revenue, profit, cash flow, or margins. The primary financial disclosure relates to capital raising capacity:
- ATM Program Capacity: Pursuant to Amendment No. 3 to the Sales Agreement, the aggregate gross sales price of common stock available for issuance is now $3,000,000,000.
- Exclusion: This $3 billion figure excludes shares of common stock previously sold under the Sales Agreement prior to the execution of Amendment No. 3.
Material Changes and Corporate Actions
Executive Departure: Peter J. Bulgarelli, Executive Vice President, Outpatient Medical & Research, and President and CEO of Lillibridge Healthcare Services, Inc., retired effective May 1, 2026. A separation and release agreement was executed on May 12, 2026, providing for a prorated 2026 bonus contingent on a release of claims and compliance with restrictive covenants.
Annual Meeting Results: The 2026 Annual Meeting was held on May 13, 2026, with 93.50% of outstanding shares represented. All three proposals were approved:
- Proposal 1 (Election of Directors): All 12 nominees were elected. Vote counts ranged from approximately 392 million to 429 million votes "For."
- Proposal 2 (Say-on-Pay): Advisory approval of Named Executive Officer compensation received 392,256,709 votes "For" versus 35,413,128 "Against."
- Proposal 3 (Auditor Ratification): Ratification of KPMG LLP as independent auditor received 437,540,505 votes "For" versus 6,812,572 "Against."
Guidance, Outlook, and Risks
The filing contains standard forward-looking statements regarding expectations and strategies but provides no specific quantitative guidance or outlook for future periods. Management highlighted significant risk factors, including:
- Exposure to evolving governmental healthcare policies and reimbursement programs.
- Macroeconomic conditions, including inflation, interest rates, and credit market availability.
- Reliance on third-party managers and tenants for property operations.
- Operational risks related to cybersecurity, artificial intelligence, and natural disasters.
- REIT compliance requirements and ownership limits.
Investor Verification Checklist
- Verify the full text of the Separation Agreement with Peter J. Bulgarelli in the upcoming Form 10-Q for the quarter ending June 30, 2026.
- Review the full text of Amendment No. 3 to the ATM Sales Agreement (Exhibit 1.1) to confirm specific terms and conditions.
- Monitor the Company's ability to access capital markets given the $3 billion ATM capacity and current interest rate environment.
- Assess the impact of the executive departure on the Outpatient Medical & Research segment strategy.